Rhei Pharmaceuticals was told by the SFDA that its application for China marketing of MuGard™ is complete. MuGard is an oral mouthwash that protects against oral mucositis, a side effect of chemotherapy and radiation treatment. Rhei expects final marketing approval of the product in the second half of the year. MuGard was developed by Access Pharmaceuticals in the US. Rhei, a privately held company based in Hong Kong, also has offices in China and the US. Rhei specializes in bringing western drugs to China. More details....

Stock Symbol: (OTCBB: ACCP)     Share this with colleagues: